Glycans, as is said to be the face of cells, greatly change the structure depending on the state of the cell. It is known that specific changes in the glycan structure occur in canceration, and various diagnostic and therapeutic drugs are under development using glycans as the drug discovery targets. Changes in glycan structure caused by canceration depend on the type of cancer, but common characteristics include followings:<\/p>\n
(1) Increase in multi-branching of N-type sugar chains However, in addition to these, there seems to be a feature that the amount of glycan modification increases when it becomes cancerous, and the high mannose structure increases, too. Based on the cited papers above, I will summarize the strategy of glycan targeted drug discovery as follows.<\/p>\n Glycans, as is said to be the face of cells, greatly change the structure depending on the state of the cell. <\/p><\/div>\n
\n(2) Shortening of O-type glycan chains
\n(3) Increase in terminal-sialic acid modification
\nhttps:\/\/jitc.bmj.com\/content\/8\/2\/e001222.long<\/a><\/p>\n
\nhttps:\/\/pubmed.ncbi.nlm.nih.gov\/32143591\/<\/a><\/p>\n\n